MolecuLight Inc.

MolecuLight Inc. manufactures advanced wound care diagnostic imaging devices that detect harmful bacteria in wounds using real-time, non-invasive fluorescence imaging technology. The company's flagship product line includes the MolecuLight i:X and MolecuLight DX platforms, which provide multimodal imaging capabilities for wound assessment. The DX model features integrated thermal imaging for non-contact skin temperature visualization with ±0.5°C accuracy, automated digital wound measurement with auto-depth capability, and comprehensive wound documentation. Both devices are Class II FDA-cleared and CE-marked, validated for bacterial detection and infection identification across all skin tones. The imaging platform is EHR-integrated with all leading electronic health record systems and features HIPAA and SOC II Type 2 compliance for secure data management. Clinical evidence demonstrates 79% greater wound area reduction by 12 weeks when harmful bacteria detected by MolecuLight are removed, and 2x more wounds healed by 12 weeks when using MolecuLight to inform wound care versus standard of care. The technology is contrast-free and requires no patient contact or stickers for measurement. Products are designed for point-of-care use in wound care settings, supporting individualized treatment protocols and evidence-based outcome tracking.